{"id":22886,"date":"2022-11-09T12:40:23","date_gmt":"2022-11-09T11:40:23","guid":{"rendered":"https:\/\/porib.com\/?p=22886"},"modified":"2022-11-18T12:58:19","modified_gmt":"2022-11-18T11:58:19","slug":"presa-m-vicente-d-calles-a-salinas-ortega-l-naik-j-garcia-lf-soto-j","status":"publish","type":"post","link":"https:\/\/porib.com\/en\/presa-m-vicente-d-calles-a-salinas-ortega-l-naik-j-garcia-lf-soto-j\/","title":{"rendered":"Presa M, Vicente D, Calles A, Salinas-Ortega L, Naik J, Garc\u00eda LF, Soto J"},"content":{"rendered":"<div class=\"col80\">\n<p class=\"miniatura_foto\" style=\"text-align: justify;\"><strong><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-14157 alignleft\" src=\"https:\/\/porib.com\/wp-content\/uploads\/2021\/09\/ISPOR.jpg\" alt=\"\" width=\"120\" height=\"120\" \/><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong style=\"text-align: justify;\">Presa M, Vicente D, Calles A, Salinas-Ortega L, Naik J, Garc\u00eda LF, Soto J<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<\/div>\n<div class=\"col80\">\n<div class=\"col80p\">\n<h6><\/h6>\n<h6 style=\"text-align: justify;\">Lorlatinib as a first-line treatment for ALK+ advanced Non-Small Cell Lung Cancer: a cost-effectiveness analysis in Spain<\/h6>\n<h6 style=\"text-align: justify;\"><strong>25th Annual European Congress International Society for Pharmacoeconomics &amp; Outcomes Research (ISPOR). Viena (Austria). 06-09 nov 2022<\/strong><\/h6>\n<p><a href=\"https:\/\/porib.com\/wp-content\/uploads\/2022\/11\/323.pdf\" target=\"_blank\" rel=\"noopener\">POSTER<\/a><\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Presa M, Vicente D, Calles A, Salinas-Ortega L, Naik J, Garc\u00eda LF, Soto J &nbsp; &nbsp; Lorlatinib as a first-line treatment for ALK+ advanced Non-Small Cell Lung Cancer: a cost-effectiveness analysis in Spain 25th Annual European Congress International Society for Pharmacoeconomics &amp; Outcomes Research (ISPOR). Viena (Austria). 06-09 nov 2022 POSTER<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"quote","meta":{"footnotes":""},"categories":[116,928,246],"tags":[],"class_list":["post-22886","post","type-post","status-publish","format-quote","hentry","category-ace-acu-tipo-de-proyecto","category-oncologia","category-international-society-of-pharmacoeconomics-and-outcomes-research","post_format-post-format-quote"],"translation":{"provider":"WPGlobus","version":"2.10.3","language":"en","enabled_languages":["es","en"],"languages":{"es":{"title":true,"content":true,"excerpt":false},"en":{"title":false,"content":false,"excerpt":false}}},"_links":{"self":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/22886"}],"collection":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/comments?post=22886"}],"version-history":[{"count":2,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/22886\/revisions"}],"predecessor-version":[{"id":22895,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/22886\/revisions\/22895"}],"wp:attachment":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/media?parent=22886"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/categories?post=22886"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/tags?post=22886"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}